Literature DB >> 12481546

Human prostacyclin receptor.

Emer M Smyth1, Garret A FitzGerald.   

Abstract

Prostacyclin, a member of the eicosanoid family of lipid mediators, is the major product of arachidonic acid metabolism formed in the marcovascular endothelium. It is a potent vasodilator, antithrombotic, and antiplatelet agent that mediates it effects through a membrane-associated receptor termed the IP. Cloning of the cDNA for IP, from human and other species, indicated its membership of the G protein-coupled receptor superfamily and has allowed detailed examination of the signaling and regulatory pathways utilized by this receptor. This article examines the current state of knowledge of the IP, its signaling and regulation, and its biological role in vivo and examines the possible existence of multiple PGI2 receptor sites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12481546     DOI: 10.1016/s0083-6729(02)65063-0

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  11 in total

1.  Catalog of 178 variations in the Japanese population among eight human genes encoding G protein-coupled receptors (GPCRs).

Authors:  Susumu Saito; Aritoshi Iida; Akihiro Sekine; Saori Kawauchi; Shoko Higuchi; Chie Ogawa; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2003-08-30       Impact factor: 3.172

2.  The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.

Authors:  Séverine Roger; Cécile Badier-Commander; Jérôme Paysant; Alex Cordi; Tony J Verbeuren; Michel Félétou
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 3.  Prostacyclin receptor regulation--from transcription to trafficking.

Authors:  C Midgett; J Stitham; K A Martin; J Hwa
Journal:  Curr Mol Med       Date:  2011-10       Impact factor: 2.222

Review 4.  PGI2 as a regulator of CD4+ subset differentiation and function.

Authors:  Madison G Boswell; Weisong Zhou; Dawn C Newcomb; R Stokes Peebles
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-08-12       Impact factor: 3.072

5.  RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists.

Authors:  Keith R Bley; Anindya Bhattacharya; Don V Daniels; Joel Gever; Alam Jahangir; Counde O'Yang; Steven Smith; Dinesh Srinivasan; Anthony P D W Ford; Mary-Frances Jett
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 6.  Prostaglandins and inflammation.

Authors:  Emanuela Ricciotti; Garret A FitzGerald
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-05       Impact factor: 8.311

Review 7.  Endothelium-mediated control of vascular tone: COX-1 and COX-2 products.

Authors:  Michel Félétou; Yu Huang; Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

8.  Prostacyclin: an inflammatory paradox.

Authors:  Jeremiah Stitham; Charles Midgett; Kathleen A Martin; John Hwa
Journal:  Front Pharmacol       Date:  2011-05-13       Impact factor: 5.810

9.  Comprehensive expression analysis of prostanoid enzymes and receptors in the human endometrium across the menstrual cycle.

Authors:  Rob D Catalano; Martin R Wilson; Sheila C Boddy; Henry N Jabbour
Journal:  Mol Hum Reprod       Date:  2010-11-26       Impact factor: 4.025

10.  Temporal expression and signalling of prostacyclin receptor in the human endometrium across the menstrual cycle.

Authors:  S Battersby; H O D Critchley; A J de Brum-Fernandes; H N Jabbour
Journal:  Reproduction       Date:  2004-01       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.